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Background: The need for structured education programmes for type 2 diabetes is a high priority for many
governments around the world. One such national education programme in the United Kingdom is the DESMOND
Programme, which has been shown to be robust and effective for patients in general. However, these programmes
are not generally targeted to people with intellectual disabilities (ID), and robust evidence on their effects for this
population is lacking. We have adapted the DESMOND Programme for people with ID and type 2 diabetes to
produce an amended programme known as DESMOND-ID.
This protocol is for a pilot trial to determine whether a large-scale randomised trial is feasible, to test if DESMOND-ID is
more effective than usual care in adults with ID for self-management of their type 2 diabetes, in particular as a means to
reduce glycated haemoglobin (Hb1Ac), improve psychological wellbeing and quality of life and promote a healthier
lifestyle. This protocol describes the rationale, methods, proposed analysis plan and organisational and administrative
details.
Methods/Design: This trial is a two arm, individually randomised, pilot trial for adults with ID and type 2 diabetes, and
their family and/or paid carers. It compares the DESMOND-ID programme with usual care. Approximately 36 adults with
mild to moderate ID will be recruited from three countries in the United Kingdom. Family and/or paid carers may also
participate in the study. Participants will be randomly assigned to one of two conditions using a secure computerised
system with robust allocation concealment. A range of data will be collected from the adults with ID (biomedical,
psychosocial and self-management strategies) and from their carers. Focus groups with all the participants will assess
the acceptability of the intervention and the trial.
Discussion: The lack of appropriate structured education programmes and educational materials for this population
leads to secondary health conditions and may lead to premature deaths. There are significant benefits to be gained
globally, if structured education programmes are adapted and shown to be successful for people with ID and other
cognitive impairments.
Trial registration: Registered with International Standard Randomised Controlled Trial (identifier: ISRCTN93185560) on
10 November 2014.
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Type 2 diabetes (T2D) affects approximately one in twenty
people across Europe and accounts for an uneven use of
healthcare resources [15]. Traditional management of T2D
is based on medication, diet and lifestyle modifications, and
managed by the patient’s GP, practice nurse and/or diabetes
specialist nurse (DNS), with three monthly visits to the
health centre [6]. However, many patients find this manage-
ment strategy difficult to implement and sustain [22]. The
need for structured, rather than ad hoc, patient education
programmes for diabetes using both a theoretical rationale
and cognitive reframing has a high priority on the govern-
mental healthcare agenda in the United Kingdom ([10,21].
One specific national programme, the Diabetes and Self-
Management for Ongoing and Newly Diagnosed patients
with T2D Programme (DESMOND), has been shown to be
a robust and effective programme for those with T2D, illus-
trating improvements in weight loss, depression, smoking
cessation, beliefs about diabetes and greater perceived re-
sponsibility [5,11,16,23,28].
There is growing evidence to show that as people with
ID live longer, they are becoming more susceptible to a
range of chronic physical health conditions, such as re-
spiratory disease, cardiovascular disease, gastrointestinal
and gall bladder cancers, and T2D [30,38]. Although
limited information exists on the incidence of diabetes
in people with ID, McVilly et al. [20] in a systematic re-
view reported that people with ID are more likely to de-
velop T2D compared to their non-ID peers:
approximately 8% (range: 3% to 18%) rather than 4% in
the non-disabled population [15]. This increased risk
may result from the ID population being more likely to
have poor nutrition, consume high fat foods, undertake
less physical activity and lead more sedentary lifestyles,
resulting in greater levels of obesity [13,34,38]). Lennox
et al. [17] in Australia, Shireman et al. [26] in Canada
and Taggart et al. [32] in Northern Ireland found that a
considerable proportion of people with ID living in the
community also had T2D, which was poorly managed.
Further, people with ID have had few opportunities to
engage in diabetes health education and screening
[26,32,33].
Internationally, reports have highlighted the continued
neglect of the health of people with ID, and that health-
care services consistently fail to work together and make
reasonable adjustments to meet the health needs of this
population [7]. With a national focus on health dispar-
ities and health promotion in the non-disabled popula-
tion, it is important that health issues that have not been
addressed are identified and acted upon for all vulner-
able populations; further illustrating the ongoing health
inequalities this population face [9].
The robust structured education programmes devel-
oped to improve the biomedical, psychosocial and self-management strategies for non-disabled people with
type 1 and 2 diabetes have not been targeted to adults
with ID [32,]. For example, Taggart, Brown & Karatzais
(2014) [33] reported that there was a lack of appropriate
information on diabetes and diet management for people
with ID, and that little emotional support was being of-
fered to adults with T2D who had ID. People with ID
rarely accessed structured education programmes for
diabetes that were offered to the non-disabled popula-
tion [29]; further illustrating ongoing inequality and
disadvantage [8]. These programmes have neither recog-
nised nor addressed the specific challenges posed by this
population’s cognitive deficits, communication difficul-
ties, low levels of literacy skills and different learning
styles. There is also a lack of adequate attention to the
need to support family and paid carers [13].
A search for other research found no trials pertaining to
diabetes education for people with ID in the World Health
Organization’s International Clinical Trials Registry Plat-
form [24]. Likewise, we have not identified any structured
education programmes being delivered internationally that
are specifically tailored to the needs of adults with ID and
T2D, or that target the carers who support this population.
In view of the burden and severity of diabetes, it is essential
that adults with ID and their family and/or paid carers are
afforded the opportunity of an evidence-informed educa-
tion programme that meets the National Institute of
Clinical Excellence Standards [21].Study objectives
With funding from Diabetes UK, Taggart and colleagues
have adapted the DESMOND Programme so that it
could be used for adults with ID in the United Kingdom.
They developed DESMOND-ID through robust delivery
and evaluation of the original DESMOND education
programme over 18 months, using video-recordings, focus
groups with service users and their carers, feedback from
two DESMOND Programme educators and observations
from three independent health professionals.
The key research question is: Can we design a feasible,
large-scale randomised trial that will resolve uncertainty
and determine whether DESMOND-ID is more effective
than usual routine care in helping adults with ID to bet-
ter self-manage their T2D to reduce their Hb1Ac? In
order to answer this question, we will conduct a small
pilot randomised trial comparing the use of the
DESMOND-ID programme with usual routine care
across three countries in the United Kingdom (Northern
Ireland, Scotland and Wales). This pilot trial will include
carefully selected secondary outcome measures (body
mass index (BMI) waist circumference, blood pressure,
lipid profiles, cardiovascular disease (CVD) risk score,
smoking, alcohol use, exercise, perceptions and severity
Figure 1 Flowchart of the study protocol. ID (intellectual disabilities).
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outcome measure of Hb1Ac.
People with ID have had very few opportunities to par-
ticipate in randomised trials about their healthcare, and
no dedicated guidance has been published on undertak-
ing a pilot randomised trial with this population. There-
fore, our development of this protocol used general
recommendations for clinical trial protocols proposed by
Tetzlaff et al. [35] and the Consolidated Standards of
Reporting Trials (CONSORT) 2010 guidelines [25]. This
pilot randomised trial will enable us to:
1. Examine the feasibility of delivering the
DESMOND-ID programme.
2. Assess eligibility, consenting rate, attendance levels,
recruitment process, loss to follow-up, compliance
and Hb1Ac of adults with ID and T2D.
3. Determine the acceptability of randomisation to
adults with ID and their carers, using retention rates
as a surrogate for acceptability [3].
4. Determine the appropriateness and the acceptability
of the outcome measures to adults with ID through
completion rates, in order to see whether the
primary outcome measure (HbA1c) and secondary
outcome measures (BMI, waist circumference, blood
pressure, lipid profiles, CVD risk score, smoking,
alcohol use, exercise, perceptions and severity of
beliefs, and quality of life) can be collected.
5. Determine the appropriateness and acceptability of
the outcome measures for the family and paid carers
through completion rates.
6. Measure compliance of the educators in delivering
the DESMOND-ID programme.
7. Estimate the treatment effect to determine whether
this suggests a clinically important effect which will
support the conduct of the full trial.
We will also conduct focus groups with adults with
ID, their carers and educators to assess the acceptability
of the intervention and the trial, and to explore their ex-
perience of the education programme, including any bar-
riers and/or facilitators to adherence.Methods/Design
The study is a two arm, individually randomised, pilot
trial in adults with ID and T2D, and their family and/or
paid carers. It compares the DESMOND-ID programme
with usual routine care. Figure 1 illustrates the pathway
through the trial. This trial corresponds to phase 2 of
the Medical Research Council’s [18,19] guidelines for
complex interventions: assessing feasibility.Recruitment
Participants
ID is defined by significant limitations in both intellec-
tual functioning and adaptive behaviour, which cover
many everyday social and practical skills, and it origi-
nates before the age of 18 years [1]. Adults with mild to
moderate ID with T2D from three countries in the
United Kingdom (Northern Ireland, Scotland and Wales)
will be recruited. A sample of 36 individuals in total will
be included in this pilot study: 18 people with ID in the
intervention group and the same number in the control
group (N = 18). There will be 12 participants from each
country; the participants will all come from one area per
country. Where there are family and/or paid carers, they
will also be recruited, and participants with ID who do
not have a carer will also be included.
Recruitment strategy
In a study that examined the demographics, health and
diabetes quality-of-care indicators of 186 people with ID
in Northern Ireland, Taggart et al. [32] highlighted the
difficulties in identifying and recruiting this population.
Therefore, potential participants will be recruited from
ID statutory services and can also be self-referred or re-
ferred by their GP, practice nurse, DSN or community
ID nurse, or by the family or paid carer in response to
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in ID day centres, health centres and so forth.
Inclusion criteria
The eligibility criteria will require that participants must
be 18 years of age or older, living in the community,
with mild to moderate ID and T2D, identified in their
clinical notes by the ID team, GP, practice nurse or
DSN. The definition of a family or paid carer is someone
who is either a family relative or residential member of
staff who engages in the support of the person with ID.
Verbal and/or written consent will be required from
people with ID and from their carers before they enter
the study.
Exclusion criteria
Participants with any one of the following criteria will
not be eligible: type 1 diabetes, a severe or profound ID
as assessed by the community ID team, inability to com-
municate and inability to give their verbal and/or written
consent.
Consent
Participants with ID will be screened for eligibility by
the primary healthcare team or community ID nurse,
who will provide the potential participants with a user
friendly information sheet and consent form. Partici-
pants with a family and/or paid carer will also be pro-
vided with an information sheet and consent form. It is
only after consent has been obtained that the research
team will contact the participant and their carer to ar-
range baseline data collection.
Randomisation
Participants with ID and their carers will be assigned to
one of two conditions via the use of a computerised ran-
dom allocation system (the RALLOC module within
Stata 13 (StataCorp LP, London, England)) with conceal-
ment to ensure that the allocation is not made before
the participant has given their consent and joined the
study. Details of each participant and their carer will be
telephoned through to a research secretary at the Ulster
University, who is not connected to the study. They will
use the information supplied by the study statistician to
inform the research team of the allocation for the par-
ticipant and, where appropriate, their carer.
Intervention
DESMOND-ID programme
The DESMOND-ID programme is an amended version
of the original DESMOND Programme that offers struc-
tured education to support adults with T2D in self-
managing their condition. The original DESMOND
Programme is based upon non-ID participants with T2Dattending a six-hour education programme in a locality
near them (that is, hospitals, community centres, health
centres and so forth), over one day or two half-days.
A detailed description of how the DESMOND-ID inter-
vention was developed and piloted has been written for
publication (Taggart, Truesdale, Stacey-Martin, Carey,
Scott, Coates, et al., unpublished work), which used the
Template for Intervention Description and Replication
(TIDieR) checklist and guide [14]. The DESMOND-ID
programme has an additional introductory education ses-
sion that is held separately for the family and paid carers in
order to support their understanding about T2D and how
it is managed. Carers gain an understanding of how the
DESMOND-ID programme works and their specific role in
supporting the person with ID throughout the programme.
The DESMOND-ID programme will be delivered in a
day-centre or health centre, over six weeks, with one
session per week, each lasting approximately two and a
half hours. The participant with ID and their carer, if ap-
propriate, will be encouraged to attend the sessions to-
gether. The education sessions will be delivered by two
trained educators who have been given two-days of
training, encompassing the DESMOND core newly diag-
nosed and DESMOND-ID programme training. The ed-
ucators can be health facilitators, community ID nurses,
DSN or dieticians. Two educators will be trained in each
of the three countries.
The educational intervention focuses on the concepts
of self-management and empowerment. The DESMOND
programme is based upon the following theories:
1. Self-regulation theory, which focuses on individuals’
illness representations as a key determinant of their
behavioural and emotional responses to illness.
2. Social learning theory, which focuses on individuals’
perceptions of their ability to carry out behaviours
and support behaviour change through developing a
personal action plan.
3. Dual process theory, which is used to guide the
educational process of addressing individuals’
current understanding of diabetes. This process is
used to actively engage participants in the learning
process.
The educational content of DESMOND-ID mirrors that
of the DESMOND Programme. The way in which educa-
tors deliver this content is adapted to make it accessible
for people with ID, and it covers the following: what dia-
betes is, food choices, monitoring, physical activity, risks
and complications and a self-management plan.
Each of the education sessions is composed of two 30
to 45 minute education sections, with a break in the
middle for refreshments. Previous work has shown that
flexibility is required in delivery and timing of the
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tration levels and learning needs.
Control group
Participants with ID and their carers who are randomly
allocated to the control group will receive usual routine
care. Discussions among the research and clinical teams
have highlighted that adults with ID and T2D and their
carers will not be offered any form of structured
education.
Routine care normally includes health centre visits
every three months in which the person will see their
primary healthcare team. Participants’ diabetes control is
reviewed within the primary healthcare team and educa-
tion is focused on problem solving and safety issues. All
those randomised to the control group will continue to
receive usual routine care, and be asked to complete the
data gathering instruments and allow appropriately
qualified members of the research team to access to
their clinical results at baseline and during the follow-up
period. If the programme is found to be effective, partic-
ipants in the control group will be offered the
DESMOND-ID education programme by the trained ed-
ucators at the end of the study.
Training of educators delivering the intervention
Six educators will be recruited and trained to deliver the
DESMOND-ID education programme; two educators in
each country. A two-day educator training programme
will be provided by experienced DESMOND Programme
trainers involved in adapting the original DESMOND
Programme for adults with ID. Followed by one day
of observation and mentorship of educators delivered
in each of the sites, no training will be offered to the
primary healthcare team in the control group and
they will not be responsible for any intervention
patients.
Measures for participants with intellectual disabilities
This trial will use the same measures as used in previous
studies that have examined the original DESMOND
Programme to assess biomedical and psychosocial out-
comes [10,11,16,23,28]. This will allow for a comparison
of the effects in the non-ID and ID populations. The se-
lection of these measures also adheres to the core out-
come set (COS) guidelines identified by Williamson et
al. [40], which will allow us to compare and contrast the
effects of different interventions in ways that maximise
power and minimise bias.
Demographic data
A profile of the participants with ID will be collected at
the pre-intervention stage in order to describe factors
such as age, gender, with whom they live, functioning,communication, physical and mental health status, dur-
ation of diabetes, treatment regimen and self-monitoring
practices.
Biomedical data
Data on HbA1c, BMI, waist circumference, blood pres-
sure, blood lipid levels (total, high-density lipoprotein,
low-density lipoprotein and cholesterol), frequency of
health centre attendance and missed appointments will be
collected from the study participants two weeks before the
education programme, and at the three-month follow-up
period directly after the intervention (see Figure 1).
Weight (kilograms), height (cm) and waist circumference
(cm) will be measured with participants dressed in light-
weight clothing, and they will be asked to remove outer
garments such as coats and jackets, shoes and belts for all
measurements. Blood pressure and blood will be taken by
the practice nurse or DSN in the participants’ health
centre. No extra blood tests will be required, because
blood samples are taken routinely at their regular health
centre check-ups by the practice nurse or DNS every three
months. The clinical data will be collected at the baseline
and at the end of the follow-up period (Figure 1). A pro
forma will be developed to facilitate rapid documentation
of the required data so that it can be promptly forwarded
to the research team.
Psychosocial or behaviour measures
Participants with ID will complete the following mea-
sures at baseline and at three months after the
intervention:
1. The Illness Perception Questionnaire-Revised [39]
will examine participants’ understanding of diabetes
(illness coherence score), perception of the duration
of their illness (timeline score) and the perception of
their ability to affect the course of their diabetes
(personal responsibility score). This scale has not
been validated for adults with ID.
2. The Diabetes Illness Representation Questionnaire
[27] will examine participants’ perceptions about the
seriousness and impact of diabetes. This scale has
not been validated for adults with ID.
3. The Summary of Diabetes Self-Care Activities
Questionnaire [36] will examine participants’ diet
and smoking patterns. This scale has not been
validated for adults with ID.
4. The International Physical Activity Questionnaire [4]
will examine participants’ physical activity. This
scale has been validated for adults with ID.
The research team may need to support the person with
ID by reading the instructions and items aloud. As part of
the revision of the original DESMOND Programme,
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unpublished work) amended these standardised question-
naires in terms of wording, layout and employing a more
user friendly Likert response for the items (using smiling
faces instead of a numerical scale). The scales psychomet-
ric properties will be tested to examine if these instru-
ments are stable for this population. The statistician will
be blinded as to which participants are in the intervention
and control groups.
Measures for family and paid carers
Demographic data
A profile of the family and paid carers will be collected
once at baseline, and will include age, relationship to the
person with ID and physical and mental health status.
Psychosocial data
A slightly modified version of the Self-Efficacy for Dia-
betes Scale [12] will be used for family and paid carers
to measure their perceived ability to manage the diabetes
regime of the person with ID. A slightly modified ver-
sion of the Diabetes Family Responsibility Questionnaire
[2] will be used to measure the level of responsibility as-
sumed by family and paid carers in managing the dia-
betes regime of the persons with ID.
Although they were not used in earlier studies of the
original trials of the DESMOND Programme, these two
instruments will allow the research team to determine
whether the intervention affects the family or paid
carer’s knowledge, perceived self-efficacy and responsi-
bility in supporting the person with ID to manage his or
her T2D.
Feasibility
We will record numbers and proportions for recruit-
ment, consent, attendance, loss to follow-up and compli-
ance (number of sessions attended) on a weekly basis,
along with basic costs.
Adherence to treatment protocol
Data on the educators’ adherence to the DESMOND-ID
manual will be collected through observation by an in-
dependent observer, using a checklist based on the com-
ponents of the intervention.
Follow-up
Follow-up assessments of all biomedical and psycho-
social measurements will be undertaken three months
directly after the intervention has been delivered, with
adults with ID and their carers, for both groups across
the three countries. The biomedical measurements will
be collected by either the DNS or practice nurse, and
the psychosocial measurements will be collected by the
research associates.Quantitative analysis
The information collected will be collated and analysed.
Interpretation will centre on reflection about potential
improvements to the content of the curriculum and the
processes involved in providing education sessions.
Focus groups
Following the three-month follow-up period and the col-
lection of the associated data, the six adults with ID and
T2D and their carers who received the intervention from
each country will be invited to participate in a focus
group. The focus groups will explore participants’ expe-
riences of the DESMOND-ID programme, the barriers
and enablers to compliance with the intervention and
the acceptability of all elements of the trial. Focus
groups will also be held with the educators. The focus
groups will be semi-structured and will last 45 to
60 minutes.
Qualitative analysis
The transcripts will be subjected to a thematic content
analysis. In order to ensure the truthfulness and
consistency of the focus groups, a range of methods will
be employed. Firstly, the verbatim recording the focus
groups and transcribing of the digital files will ensure
consistent and accurate accounts of what the partici-
pants say about their experiences. Secondly, the data will
be subjected to a thematic content analysis. Thirdly, to
authenticate the key themes and sub-themes, as identi-
fied by the researcher, members of the research team
will be asked to examine a random selection of the tran-
scripts. This systematic approach will further increase
the robustness of the qualitative data, thereby enhancing
the transfer value of the findings.
Refining of materials
Results from the quantitative and qualitative stages of
this study will be used to revise the DESMOND-ID
programme further. Findings will be fed back to the Re-
search Advisory Steering Group, and final adjustments
will be made to DESMOND-ID before the full-scale ran-
domised trial.
Ethical considerations
The main ethical consideration that needs to be kept in
mind when undertaking a study with adults with ID is
capacity to consent. Capacity to decide whether to par-
ticipate and consent in the trial is of the upmost import-
ance, and this will be assessed through discussions with
the participant and/or their carers. User friendly infor-
mation sheets and consent forms have been developed
to explain the purpose and nature of the trial, and what
is involved in the education programme, if recruited to
this arm. Any questions that the person and/or their
Taggart et al. Trials  (2015) 16:148 Page 7 of 8carer have will be discussed and answered. To assess the
person’s ability to understand what is involved with this
trial, the person with ID will be asked to recall the differ-
ent parts of the study. Informed consent will then be ob-
tained; however, persons unable to understand what is
involved and unable to provide their consent will not be
included in the study.
Ethical approval, research governance and trial
sponsorship
Ethical approval has been given for this study from the
Office of Research Ethics Northern Ireland (reference
number: 14/NI/1104). The trial has been registered and
its International Standard Randomised Controlled Trials
Number (ISRCTN) is ISRCTN93185560. The Northern
Ireland Hub for Trials Methodology Research will offer
support and guidance on governance and good clinical
practice. Ulster University is the sponsor of the study.
Discussion
To our knowledge, this is the first intervention study ad-
dressing structured diabetes education for adults with ID
which is simultaneously targeting family and paid carers.
Currently, there are no structured education pro-
grammes available for adults with ID with T2D, nor for
those with type 1 diabetes. The National Institute for
Health and Care Excellence Diabetes Guidelines (21)
emphasises the importance of being offered a place on a
structured education programme within six months of
being diagnosed with T2D, in order to better self-
manage and avoid complications. The lack of planning
and availability of appropriate structured education pro-
grammes and educational materials for adults with ID
and T2D will lead to additional illness and worse health.
There are significant benefits to be gained if adapting
structured education programmes shown to be effective
in the non-ID population are beneficial for people with
ID and other cognitive impairments.
There are a number of conceptual models to show that
people with ID can successfully develop new knowledge
and skills, and therefore change their lifestyle behaviours
[34,41]. Taggart et al. [31] highlighted the importance of
addressing the person’s intrinsic motivation, to want to
change their health behaviours and to engage in self-
help, possibly by using the techniques of motivational
interviewing rather than enforcing motivation from ex-
ternal sources. Other successful techniques include of-
fering both group and one-to-one sessions with more
time flexibility, based on repetition, greater use of kines-
ics learning and role-play scenarios, and using family
and/or paid carers to support the person with ID to
maintain the behaviour changes over time. Wilson and
Goodman [41] reported that adults with mild to moderate
ID and co-morbid physical health conditions (such asdiabetes, arthritis or hypertension), could successfully par-
ticipate in chronic disease self-management programmes
if such programmes are modified. The programme also
improved this population’s access to healthcare.
The United Nations Convention on the Rights of Per-
sons with Disabilities [37] highlights the universal im-
petus for health promotion for people with ID, which
highlights the highest attainable standards of health
without discrimination. The Convention [37] further
states that parties shall ‘provide persons with disabilities
with the same range, quality and standard of free or af-
fordable healthcare and programmes as provided to
other persons, including population-based public health
programmes’. However, people with ID continue to be
excluded from many population-based public health
programmes, despite the clearly documented benefits of
health promotion.
People with ID have had very few opportunities to
participate in randomised trials about their healthcare.
This protocol is also novel because it will include adults
with ID and, where appropriate, their carers, and this
will promote self-determination, independence and bet-
ter self-management strategies. The trial will have both
national and international relevance, helping to influ-
ence how governments and service providers support
adults with ID, and their carers in proactively managing
that person’s T2D. The need for an evidence-based ap-
proach in this area is more urgent than ever, given the
likely increase in older persons with ID who will de-
velop T2D, and the growing financial burdens on
limited health services.
Trial status
Recruitment will begin in March 2015 and is scheduled
to last for eight months.
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